Clinical Trial

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-08-11
notable Enrollment reduced: 225 -> 160 participants 2026-08-11
Trial Details
NCT Number NCT05936359
Lead Sponsor Incyte Corporation
Conditions Myeloproliferative Neoplasms
Enrollment 160 participants
Start Date 2023-09-25
Primary Completion 2028-02-29 (estimated)
Study Completion 2028-02-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-10